LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

LLY

1,005.56

-1.5%↓

JNJ

229.79

+0.06%↑

ABBV

210.81

+1.69%↑

UNH

399.45

-0.62%↓

AZN

185.27

-0.71%↓

Home・Aktien・Lisata Therapeutics

L
Lisata Therapeutics

Open

3.1 -3.13

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.08

Max

3.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.3M -3M
Verkäufe	100K 100K
Gewinnspanne	-2,954
Angestellte	21

Dividenden
By Dow Jones
Nächstes Ergebnis	14. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-16M 24M
Vorheriger Eröffnungskurs	6.23
Vorheriger Schlusskurs	3.1

Lisata Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2026, 22:54 UTC

Ergebnisse

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13. Mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13. Mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Mai 2026, 23:17 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13. Mai 2026, 23:16 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13. Mai 2026, 23:15 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13. Mai 2026, 23:14 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13. Mai 2026, 23:02 UTC

Market Talk

Ergebnisse

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13. Mai 2026, 22:59 UTC

Market Talk

Ergebnisse

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13. Mai 2026, 22:24 UTC

Ergebnisse

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Organic Revenue Growth 25%>XRO.AU

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Revenue Growth 47%>XRO.AU

13. Mai 2026, 22:22 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13. Mai 2026, 22:18 UTC

Ergebnisse

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13. Mai 2026, 22:16 UTC

Ergebnisse

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13. Mai 2026, 22:13 UTC

Ergebnisse

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13. Mai 2026, 22:12 UTC

Ergebnisse

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero Did Not Declare a Dividend>XRO.AU

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13. Mai 2026, 22:09 UTC

Ergebnisse

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13. Mai 2026, 22:00 UTC

Ergebnisse

Cisco to Shed Jobs for All-In AI Push -- Update

13. Mai 2026, 21:11 UTC

Ergebnisse

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer-Vergleich

Kursveränderung

Lisata Therapeutics Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Lisata Therapeutics – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Gewinn vor Steuern

Verkäufe

Betriebsergebnis

Über Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.